Canaccord Genuity analyst William Plovanic maintained a Buy rating on TransMedics Group yesterday and set a price target of $147.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
William Plovanic has given his Buy rating due to a combination of factors that suggest a positive outlook for TransMedics Group. The aviation data indicates a potential increase in total flights and flight hours, reflecting a recovery from a seasonal decline in the previous quarter. This aligns with the company’s estimates and suggests a strong performance in the fourth quarter, comparable to earlier quarters in the year.
Additionally, the UNOS market data reveals robust trends in organ transplants, particularly in DCD liver transplants, which are ahead of expectations. These trends are considered leading indicators for TransMedics Group’s performance. The combination of aviation and transplant data supports the expectation that the company will meet or exceed revenue estimates, justifying the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $155.00 price target.
TMDX’s price has also changed slightly for the past six months – from $139.400 to $134.800, which is a -3.30% drop .